Product Name: BCA-1 Antibody (biotin)
Species Reactivity: Human
Tested Applications: ELISA, WB
Applications: ELISA:To detect hBCA-1 by direct ELISA (using 100 μL/well antibody solution) this antibody can be used at a concentration of 0.15 – 0.30 μg/mL. Used in conjunction with compatible secondary reagents, allows the detection of at least 0.2 ng/well of recombinant hBCA-1. Western Blot:To detect hBCA-1 by Western Blot analysis this antibody can be used at a concentration of 0.1 – 0.2 μg/mL. Used in conjunction with compatible secondary reagents the detection limit for recombinant hBCA-1 is 1.5 – 3.0 ng/lane, under either reducing or non-reducing conditions.
User Note: Centrifuge vial prior to opening. Reconstitute in sterile PBS containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL.
Predicted Molecular Weight:
Immunogen: Produced from sera of rabbits pre-immunized with highly pure (>98%) recombinant hBCA-1 (Human BCA-1).
Host Species: Rabbit
Purification: Anti-hBCA-1 specific antibody was purified by affinity chromatography and then biotinylated.
Physical State: Lyophilized
CAS NO.: 900305-37-5
Product: PFI-4
Buffer:
Concentration:
Storage Conditions: BCA-1 antibody is stable for at least 2 years from date of receipt at -20˚C. The reconstituted antibody is stable for at least two weeks at 2-8˚C. Frozen aliquots are stable for at least 6 months when stored at -20˚C. Avoid repeated freeze-thaw cycles.
Clonality: Polyclonal
Conjugate: Biotin
Alternate Names: BLC, BCA1, ANGIE, BCA-1, BLR1L, ANGIE2, SCYB13, BLC, C-X-C motif chemokine 13, Angie
Accession NO.: O43927
Protein Ino: 7673945
Official Symbol: CXCL13
Geneid: 10563
Background: B lymphocyte chemoattractant is a CXC chemokine strongly expressed in the follicles of the spleen, lymph nodes, and Peyers patches. It preferentially promotes the migration of B lymphocytes (compared to T cells and macrophages), apparently by stimulating calcium influx into, and chemotaxis of, cells expressing Burkitts lymphoma receptor 1 (BLR1).
PubMed ID:http://aac.asm.org/content/53/11/4845.abstract
